42 results about "Bacteriophage Therapy" patented technology

The present invention relates to phage isolates having a strong lytic activity against pathogenic Enterobacteriaceae such as Escherichia coli and / or Salmonella strains and their use in various human or pet food products for the treatment or prevention of bacterial diseases caused by pathogenic Enterobacteriaceae such as Escherichia coli, in particular for phage therapy of pediatric gastroenteritis, or Salmonella infection. It also relates to human or pet food products prepared thereof.

The present invention relates to the use of bacteriophages to treat infections diseases. The invention provides a method for intermediate to large scale commercial production of bacteriophage composition, wherein the method reduces the production volume and elevates production yield. The invention further relates to improved bacteriophage compositions comprising specific sugars that reduce or abolish the bacterial phage-neutralizing activity.

The objective of the present invention is to provide chimeric phage-derived particles, that may be used as safe food grade vehicles to for presenting various factors (e.g. antigens, virulence proteins, receptors, ligands, etc.) for living cells. In addition to at least one normal phage or virus component the particles comprise at least one additional factor that is not encoded by the genetic material of the chimeric particle. Applications for such particles include, but are not limited to, vaccine development, pathogen neutralization, chemical binding and / or neutralization (e.g. toxins), and competitive exclusion. In addition, this technology may be used to extend the retention time of phage particles during phage therapy and / or specifically target a given particle for a biofilm.

The present invention is directed to bacteriophage therapy, using methods which enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects. The HDS normally reduces the number of bacteriophage in an animal, which decreases the efficiency of the bacteriophage in killing the host bacteria present during an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes by physico-chemical alteration of the bacteriophage surface proteins, so that the altered bacteriophage remain active in the body for longer periods of time than the unmodified bacteriophage.

The invention discloses drug-resistant coli phage and application thereof. The classification of the drug-resistant coli phage is named as Escherichia phage vB_EcoP-EG1, the reservation number is CCTCC M 2018562, and the preservation date is August 21, 2018. The phage Escherichia phage vB_EcoP-EG1 has stable properties, a short life cycle and high lysis ability to host bacteria. The results of a genome and a protein map show that the phage Escherichia phage vB_EcoP-EG1 does not encode toxic proteins. At the same time, the phage Escherichia phage vB_EcoP-EG1 can infect and lyse a plurality of strains of clinically and randomly isolated multi-drug resistant escherichia coli, and particularly has a good killing effect on uropathogenic escherichia coli. In conclusion, Escherichia phage vB_EcoP-EG1 is a good candidate phage for phage therapy, can be used as a single preparation or mixed with other phages to form a cocktail preparation for fighting against infection caused by the clinical multi-drug resistant escherichia coli.

The invention relates to an aeromonas salmonicida phage, a bactericidal composition comprising the same and an application of the bactericidal composition. The phage is capable of quickly inhibiting growth of Atlantic aeromonas salmonicida within a short period of time and inhibiting generation of resistance of the pathogenic bacterium phage. In addition, the bactericidal composition comprising the phage is safe and effective, and is high in specificity and low in production cost, and the disadvantages of single phagotherapy are compensated in the control process of pathogenic bacterium.

The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

The invention relates to aeromonas salmonicida bacteriophage, a sterilization composition with the same and application of the same. The bacteriophage is capable of rapidly inhibiting growth of Atlantic aeromonas salmonicida within a short time, and inhibiting generation of resistance of the pathogenic bacterium bacteriophage. In addition, the sterilization composition with the bacteriophage is safe and effective, high in specificity and low in production cost, and defects of single bacteriophage phagotherapy can be made up in the control process of pathogenic bacteria.

The invention relates to aeromonas salmonicida bacteriophage, a sterilization composition with the same and application of the same. The bacteriophage is capable of rapidly inhibiting growth of Atlantic aeromonas salmonicida within a short time, and inhibiting generation of resistance of the pathogenic bacterium bacteriophage. In addition, the sterilization composition with the bacteriophage is safe and effective, high in specificity and low in production cost, and defects of single bacteriophage phagotherapy can be made up in the control process of pathogenic bacteria.

The invention relates to a Vibrio alginolyticus bacteriophage and a bactericidal composition containing the same. The bacteriophage can rapidly inhibit the growth of Vibrio alginolyticus in a short period of time and is long in the duration of inhibitory effect. The bactericidal composition containing the bacteriophage is safe and effective, has strong specificity and low production cost, and makes up for the deficiencies of single-bacteriophage therapy during the control of pathogenic bacteria.

The invention belongs to the technical field of research and development of Vibrio alginolyticus phages and particularly relates to a wide-lytic-spectrum Vibrio alginolyticus phage, composition thereof, and a kit. The wide-lytic-spectrum Vibrio alginolyticus phage is Vibrio alginolyticus phage VAP7 collected under CCTCC NO: M 2018767. The inventio also discloses application of the Vibrio alginolyticus phage, a Vibrio alginolyticus phage composition, or a reagent or a kit containing the Vibrio alginolyticus phage or the Vibrio alginolyticus phage composition in the killing and / or prevention ofVibrio microbes. The Vibrio alginolyticus phage herein has a wide host range, has high toxicity to host bacteria under low concentration, can well propagate on nonpathogenic bacterial hosts, and is suitable for large-scale industrial production. Good strain resources can be provided for the application of phagotherapy.

The present invention relates to a bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia colis trains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

The invention relates to a Vibrio alginolyticus bacteriophage and a bactericidal composition containing the same. The bacteriophage can rapidly inhibit the growth of Vibrio alginolyticus in a short period of time and is long in the duration of inhibitory effect. The bactericidal composition containing the bacteriophage is safe and effective, has strong specificity and low production cost, and makes up for the deficiencies of single-bacteriophage therapy during the control of pathogenic bacteria.

This invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to Pseudomonas aeruginosa, or a progeny bacteriophage thereof having a RFLP (Restriction fragment length polymorphism) DNA profile substantially equivalent to the bacteriophage MPK6. The present invention provides a bacteriophage MPK6 or a progeny bacteriophage thereof capable of treating a Pseudomonas aeruginosa infection disease, and suggests an anti-bacterial activity of MPK6 and its progeny bacteriophage using a mammalian and non-mammalian infection model. According to the present invention, the present bacteriophage MPK6 or progeny bacteriophage thereof represents very effective efficacy on treatment of P. aeruginosa-induced peritonitis-sepsis.

The invention relates to lytic vibrio phage ValDsh-1, a sterilization composition containing the phage and application of the lytic vibrio phage ValDsh-1 and the sterilization composition. The phage can fast inhibit the growth of vibrio within a short time; in addition, the inhibition effect can be maintained for a long time. In addition, the sterilization composition of the phage is safe, effective, high in specificity and is low in production cost; in the pathogen control process, the defects of a single phage treatment method are overcome.

The invention belongs to the technical field of biology, and particularly relates to a broad-spectrum escherichia coli phage and an application thereof. The escherichia coli phage WXLECP008 provided by the invention is a virulent phage, the phage has tolerance under the conditions that the pH is 4-10 and the temperature is minus 80 DEG C to 65 DEG C, and the titer of the phage is 3.5 * 10 <10> pfu / mL when the phage is cultured for 8 hours under the condition that the MOI is 0.1. The escherichia coli phage provided by the invention is a phage with broad spectrum and wide splitting decomposition spectrum, is high in titer and high in safety, can be massively propagated in non-pathogenic host bacteria, and can be used for large-scale fermentation production. The phage provided by the invention can provide an excellent strain resource for developing a bacteriophage therapy, has a good application and development prospect, and is suitable for popularization and application.

The invention relates to a Vibrio alginolyticus bacteriophage and a bactericidal composition containing the same. The bacteriophage can rapidly inhibit the growth of Vibrio alginolyticus in a short period of time and is long in the duration of inhibitory effect. The bactericidal composition containing the bacteriophage is safe and effective, has strong specificity and low production cost, and makes up for the deficiencies of single-bacteriophage therapy during the control of pathogenic bacteria.

The invention belongs to the technical field of research and development of vibrio alginolyticus phage and particularly relates to a high temperature resistant vibrio alginolyticus phage, as well as acomposition and kit thereof. The vibrio alginolyticus phage VAP9 has a preservation number of CCTCC NO:M 2018766. The invention further discloses application of the vibrio alginolyticus phage, or a vibrio alginolyticus phage composition, or a reagent or kit containing the vibrio alginolyticus phage or vibrio alginolyticus phage composition in killing and / or preventing vibrio microbes. The vibrioalginolyticus phage has a wide host range, still has high toxicity on host bacteria under a low concentration, can be well reproduced on a nonpathogenic bacterial host and can realize large-scale industrial production. an excellent strain resource can be provided to application of phagotherapy.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains and cocktails thereof, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and / or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.

The invention relates to a Vibrio parahaemolyticus bacteriophage and a bactericidal composition containing the same. The bacteriophage can rapidly inhibit the growth of Vibrio parahaemolyticus in a short period of time and is long in the duration of inhibitory effect. The bactericidal composition containing the bacteriophage is safe and effective, has strong specificity and low production cost, and makes up for the deficiencies of single-bacteriophage therapy during the control of pathogenic bacteria.

The invention discloses a polypeptide for prolonging the blood circulation time of a bacteriophage, the bacteriophage, a method for screening the polypeptide and application of the polypeptide and thebacteriophage. The polypeptide is carried by the bacteriophage, and the bacteriophage has a function of prolonging the blood circulation time. The polypeptide, the bacteriophage, the method and the application have the advantage of important significance in bacteriophage therapy.

The invention discloses an administration method for protecting bacteriophage activity and application thereof. The method utilizes host bacteria of the bacteriophage to protect the bacteriophage, thereby enhancing resistance of the bacteriophage. The method aims to help the bacteriophage to break body immunization barriers, so that the bacteriophage can complete a first propagation under protection of the host bacteria and release numerous filial generation bacteriophages and further singularly invade and crack infectious bacteria. The method of the invention can be applied to bacteriophage therapies of infections of all parts and organs of body caused by prokaryotic and eukaryotic cell microbes. The invention reduces interference of body resistance on the bacteriophage therapy, amplifies and magnifies treatment dosage and treatment effect of the bacteriophage, and provides a new, practical and effective administration method for enforcing clinical bacteriophage treatment on microbe infectious diseases.

A method of selecting a bacteriophage formulation is described wherein the method comprises storing bacterial infection / contamination data at one or more treatment sites in a spatio-temporal infection database, the database comprising at least one of the following data fields: (1) clinical indications, (2) bacterial identification, (3) clinical effects, (4) bacteriophage resistance status, (5) a bacteriophage resistance status, and (6) a bacteriophage resistance status. (5) a bacteriophage susceptibility attribute, (6) an antibiotic susceptibility attribute, and / or (7) a laboratory test result related to any one of (1) to (6); identifying one or more infections associated with the treatment site during the historical period of time by analyzing the data fields (1) to (7) in the database based at least on one or more of the frequency of infections / contamination, geo-clustering of infections / contamination, and / or bacteriophage usage data, thereby identifying one or more bacteriophages suitable for inclusion in the bacteriophage formulation; and generating a selection list of bacteriophages to be included in the bacteriophage preparation. Uses of the formulations are also described.